BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst (Nasdaq:BCRX) announced inducement restricted stock unit grants to six newly hired employees covering an aggregate of 65,850 RSUs, granted as of March 2, 2026 under Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date and are subject to the company’s Inducement Equity Incentive Plan and individual RSU agreements.

News Market Reaction – BCRX

-1.38%

-1.38% Session close to close

In the Mar 4 session, BCRX declined 1.38%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine inducement RSU grants totaling 65,850 shares to six new employees,...

Analysis

This announcement details routine inducement RSU grants totaling 65,850 shares to six new employees, vesting over four years under Nasdaq Listing Rule 5635(c)(4). It follows a series of stronger fundamental updates, including record 2025 results and expanded HAE data. Investors may view these grants in the context of ongoing hiring and equity-based compensation practices, watching future filings and earnings updates for any changes in overall share count, profitability, or strategic direction.

Key Figures

RSU shares granted: 65,850 shares Employees granted RSUs: 6 employees Vesting schedule: 4 annual installments +1 more

4 metrics

RSU shares granted 65,850 shares Aggregate RSUs to six new employees as of March 2, 2026

Employees granted RSUs 6 employees Newly hired employees receiving inducement RSUs

Vesting schedule 4 annual installments RSUs vest over four years, starting one year after grant

Grant date March 2, 2026 Date RSUs were granted under Nasdaq Listing Rule 5635(c)(4)

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 26	Full-year earnings	Positive	+4.6%	Record 2025 revenue, operating profit, and maintained 2026 revenue guidance.
Feb 17	Investor conference	Positive	+2.8%	Announcement of participation at major health care investor conference.
Feb 11	Clinical data updates	Positive	+4.4%	Multiple HAE abstracts including ORLADEYO and navenibart interim results.
Feb 05	Earnings date notice	Neutral	-2.8%	Scheduling of Q4 2025 results call and webcast logistics.
Feb 05	Inducement equity grants	Neutral	-2.8%	Stock options and RSUs granted to 24 new hires under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news with strong operational or clinical content has aligned with positive price reactions, while administrative items like grant announcements or event notices have seen flat-to-negative moves.

Recent Company History

Over the last month, BioCryst has reported strong fundamentals and strategic progress. Full-year 2025 results on Feb 26 showed record revenue and profit, with the stock rising 4.64%. Clinical and conference updates in early February also coincided with gains of 4.43% and 2.81%. In contrast, routine items such as earnings-date notices and prior inducement grants on Feb 5 saw declines of -2.8%, framing today’s small RSU grants as part of ongoing compensation practices.

Key Terms

restricted stock units (rsus), nasdaq listing rule 5635(c)(4), inducement equity incentive plan, restricted stock unit agreement

4 terms

restricted stock units (rsus) financial

"granted six newly-hired employees restricted stock units (RSUs) covering"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

nasdaq listing rule 5635(c)(4) regulatory

"RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement equity incentive plan financial

"subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan"

An inducement equity incentive plan is a program that grants employees or executives company shares or stock options to motivate and reward their work, often as a way to attract new talent. It aligns their interests with the company's success, encouraging them to contribute to long-term growth. For investors, such plans can influence a company's stock performance and overall financial health by motivating key personnel.

restricted stock unit agreement financial

"and a restricted stock unit agreement covering the grant."

A restricted stock unit agreement is a written contract between a company and an individual that describes a promise to deliver company shares or cash later, subject to conditions such as time-based vesting or performance targets. Think of it like a timed gift: the recipient only receives the shares if they meet the agreed conditions. Investors care because these agreements create future share issuance, affect potential dilution, corporate expenses and incentives for insiders, and influence when insiders may sell shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,850 shares of BioCryst common stock. The RSUs were granted as of March 2, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.

About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

FAQ

What did BioCryst (BCRX) announce on March 4, 2026 about RSU grants?

BioCryst granted an aggregate of 65,850 RSUs to six new hires, effective March 2, 2026. According to the company, the awards were made as inducements under Nasdaq Listing Rule 5635(c)(4) and are governed by the Inducement Equity Incentive Plan and RSU agreements.

When do the BioCryst (BCRX) inducement RSUs vest and what are the conditions?

The RSUs vest in four equal annual installments starting on the one-year anniversary of the grant date. According to the company, each installment vests only if the new employee continues service with BioCryst and per the RSU agreement terms.

How many employees received inducement awards in the BioCryst (BCRX) filing dated March 4, 2026?

Six newly hired employees received inducement awards of RSUs from BioCryst. According to the company, the awards total 65,850 shares and were granted as material inducements for entering employment with BioCryst.

Under which plan were the BioCryst (BCRX) inducement RSUs granted?

The RSUs were granted under BioCryst’s Inducement Equity Incentive Plan and covered by individual RSU agreements. According to the company, awards comply with Nasdaq Listing Rule 5635(c)(4) for inducement grants.

Do the BioCryst (BCRX) inducement RSUs affect shareholder dilution immediately?

The RSUs represent potential future issuance of 65,850 shares but do not necessarily dilute outstanding shares until vesting and settlement. According to the company, issuance depends on vesting, continued service, and RSU agreement terms.